Results 261 to 270 of about 31,601 (273)

Biosimilars.

PDA journal of pharmaceutical science and technology, 2016
  +5 more sources

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis

Arthritis and Rheumatology, 2018
Michael E Weinblatt
exaly  

Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial

The Lancet Gastroenterology and Hepatology, 2018
Anne S Strik, M T Nurmohamed, Peter Bossuyt   +2 more
exaly  

Biosimilarity

2018
openaire   +2 more sources

Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!

BioDrugs, 2019
Isabelle Huys, Arnold G Vulto, Steven R A Simoens   +2 more
exaly  

Analytical characterization of biosimilar antibodies and Fc-fusion proteins

TrAC - Trends in Analytical Chemistry, 2013
Alain Beck, Daniel Ayoub, Christine Carapito   +2 more
exaly  

The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis

British Journal of Dermatology, 2017
D Thaçi
exaly  

Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study

Annals of the Rheumatic Diseases, 2017
Stanley B Cohen, Mark C Genovese, Ernest H Choy   +2 more
exaly  

Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

British Journal of Dermatology, 2018
Andrew Blauvelt
exaly  

To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry

Annals of the Rheumatic Diseases, 2019
Bente Glintborg, Anne Gitte Loft, Oliver Hendricks   +2 more
exaly